These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 1918223)

  • 1. Ceftriaxone in treatment of serious infections. Urinary tract infections.
    Sanders WE
    Hosp Pract (Off Ed); 1991 Sep; 26 Suppl 5():48-51; discussion 63-4. PubMed ID: 1918223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increasing antibiotic resistance among uropathogens isolated during years 2006-2009: impact on the empirical management.
    Mohammad-Jafari H; Saffar MJ; Nemate I; Saffar H; Khalilian AR
    Int Braz J Urol; 2012; 38(1):25-32. PubMed ID: 22397779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of ceftriaxone in the treatment of severe infections in hospitalized patients.
    Alexopoulos E; Anassis P; Hadjidimitrou C; Papadimitriou M
    Chemioterapia; 1987 Jun; 6(2 Suppl):380-1. PubMed ID: 3509452
    [No Abstract]   [Full Text] [Related]  

  • 4. Ceftriaxone: a third-generation cephalosporin.
    Nahata MC; Barson WJ
    Drug Intell Clin Pharm; 1985 Dec; 19(12):900-6. PubMed ID: 3910386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-daily therapy with ceftriaxone compared with daily multiple-dose therapy with cefotaxime for serious bacterial infections: a randomized, double-blind study.
    Mandell LA; Bergeron MG; Ronald AR; Vega C; Harding G; Saginur R; Feld R; Duperval R; Landis SJ; Miedzinski LJ
    J Infect Dis; 1989 Sep; 160(3):433-41. PubMed ID: 2668427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ceftriaxone in chemoprophylaxis and therapy of urinary tract infections.
    Pisani E; Dell'Acqua S; Morosini D; Mandressi A; Trinchieri A
    Eur Surg Res; 1989; 21 Suppl 1():36-42. PubMed ID: 2661233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparative study of intravenous ceftriaxone followed by oral cefixime versus ceftriaxone alone in the treatment of severe upper urinary tract infections].
    Regnier B
    Presse Med; 1989 Oct; 18(32):1617-21. PubMed ID: 2530546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outpatient treatment of serious community-acquired pediatric infections using once daily intramuscular ceftriaxone.
    Dagan R; Phillip M; Watemberg NM; Kassis I
    Pediatr Infect Dis J; 1987 Dec; 6(12):1080-4. PubMed ID: 3324038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Long-term administration of ceftriaxone (Ro 13-9904) to complicated urinary tract infections].
    Oishi K; Kawakita M; Hida S; Higashi Y; Yamauchi T; Yoshida O
    Hinyokika Kiyo; 1985 Apr; 31(4):711-21. PubMed ID: 4036746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging drugs for bacterial urinary tract infections.
    Wagenlehner FM; Weidner W; Perletti G; Naber KG
    Expert Opin Emerg Drugs; 2010 Sep; 15(3):375-97. PubMed ID: 20569081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Ceftriaxone: world-wide experience with its clinical use].
    Hell K; Mendham NA; Haddad WG
    Antibiot Khimioter; 1992 Jul; 37(7):34-7. PubMed ID: 1456807
    [No Abstract]   [Full Text] [Related]  

  • 12. Outpatient treatment of febrile infants 28 to 89 days of age with intramuscular administration of ceftriaxone.
    Baskin MN; O'Rourke EJ; Fleisher GR
    J Pediatr; 1992 Jan; 120(1):22-7. PubMed ID: 1731019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Ceftriaxone and severe infections in medical resuscitation].
    Gardère JJ; de Barbeyrac B; Penouil F; Louis C; Brachet-Liermain A; Favarel-Garrigues JC
    Pathol Biol (Paris); 1987 May; 35(5):608-12. PubMed ID: 3302867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceftriaxone: in vitro studies and clinical evaluation.
    Gnann JW; Goetter WE; Elliott AM; Cobbs CG
    Antimicrob Agents Chemother; 1982 Jul; 22(1):1-9. PubMed ID: 6289734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceftriaxone in the treatment of serious infections, particularly after surgery.
    Scully BE; Neu HC
    Am J Surg; 1984 Oct; 148(4A):35-40. PubMed ID: 6091479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of a twelve-hourly ceftriaxone regimen in the treatment of serious bacterial infections.
    Maslow MJ; Levine JF; Pollock AA; Simberkoff MS; Rahal JJ
    Antimicrob Agents Chemother; 1982 Jul; 22(1):103-7. PubMed ID: 6289735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical evaluation of ceftriaxone in the treatment of neonatal infections].
    Okura K; Yamamoto H; Yamaoka K; Kubo K; Mitsuyoshi I; Haruta T; Kobayashi Y
    Jpn J Antibiot; 1988 Feb; 41(2):152-64. PubMed ID: 3286924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical evaluation of ceftriaxone in the pediatric field].
    Hoshina H; Hirosawa H; Mikuni K; Ichihashi H
    Jpn J Antibiot; 1984 Nov; 37(11):2027-33. PubMed ID: 6098699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in Bacterial Resistance Patterns of Pediatric Urinary Tract Infections and Rationale for Empirical Antibiotic Therapy.
    Gökçe İ; Çiçek N; Güven S; Altuntaş Ü; Bıyıklı N; Yıldız N; Alpay H
    Balkan Med J; 2017 Sep; 34(5):432-435. PubMed ID: 28443576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration.
    Brogden RN; Ward A
    Drugs; 1988 Jun; 35(6):604-45. PubMed ID: 3048974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.